A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).

Key facts

Study ID
NCT07205159
Run by
Forte Biosciences, Inc.
People needed
32
Starts
2025-10-23
Expected to finish
2027-03-10
Last updated by the study team
2025-11-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.